Synchronous Duodenal and Pancreatic Metastases From Clear Cell Renal Cell Carcinoma 18 Years After Nephrectomy: A Case Report Authors: Ankit Kulkarni, Suhail Sapkota, Sai Sushrutha Mudupula Vemula, Shreya Motkur, Adarsh Jha, Rutwik Pradeep Sharma, Sumugdha Rayamajhi Published: 2026 ABSTRACT ABSTRACTA 63‐year‐old man presented with melena and severe anemia 18 years after nephrectomy for clear cell renal cell carcinoma. Imaging and biopsy confirmed duodenal and pancreatic metastases mimicking pancreaticobiliary malignancy. He underwent pancreaticoduodenectomy. This case highlights delayed RCC recurrence and the role of complete resection despite significant perioperative morbidity.Keywords: duodenal neoplasms, gastrointestinal hemorrhage, neoplasm metastasis, pancreatic neoplasms, pancreaticoduodenectomy, renal cell carcinoma Introduction Renal cell carcinoma (RCC) accounts for approximately 2% of all malignancies. It is characterized by delayed and unpredictable metastatic behavior, with metastases developing in roughly a quarter of patients and recurrences reported years to decades after apparently curative nephrectomy [1, 2]. Although the lungs, lymph nodes, liver, bone, and adrenal glands are the most common sites of spread, gastrointestinal involvement is distinctly uncommon. Small bowel metastases account for only 1%–2% of cases and are usually clear cell subtype. Duodenal metastases are especially rare despite the retroperitoneal proximity of the duodenum to the right kidney [1, 3, 4]. Pancreatic metastases, though themselves uncommon at 2%–5% of pancreatic neoplasms, represent the most frequent secondary pancreatic malignancy, with RCC as the leading primary source. Concurrent duodenal and pancreatic involvement, as seen here, is exceptionally rare [5, 6, 7]. We report a 63‐year‐old man who developed clear cell RCC recurrence 18 years after right nephrectomy, presenting with symptomatic anemia and gastrointestinal hemorrhage from synchronous duodenal and pancreatic metastases and ultimately managed with pancreaticoduodenectomy. This case underscores the need to consider late metastatic recurrence in postnephrectomy patients, highlights the diagnostic challenge of a hypervascular duodenal mass mimicking a primary pancreaticobiliary tumor, and illustrates the role of complete surgical resection in isolated metastatic disease. Case History and Examination A 63‐year‐old man with a past medical history of right renal cell carcinoma (RCC) status post right nephrectomy in 2007, coronary artery disease, gastroesophageal reflux disease, and peptic ulcer disease presented with a one‐month history of progressive fatigue, generalized weakness, and exertional dyspnea, accompanied by intermittent melena for the preceding week. He reported mild intermittent epigastric discomfort without a clear relationship to meals and denied hematemesis, hematochezia, nausea, vomiting, fever, or unintentional weight loss. His home medications included aspirin 81 mg and atorvastatin 40 mg daily, and he denied use of NSAIDs or anticoagulants. Family history was notable for malignancies across three generations, including lung cancer in his mother, prostate and testicular cancer in his brother, leukemia in his sister, and testicular cancer in his son, raising the concern of an underlying hereditary cancer predisposition. On examination, the patient was tachycardic at 103 beats per minute and appeared pale. The remainder of the physical examination, including abdominal, cardiovascular, pulmonary, and neurological assessments, was unremarkable. Investigations and Diagnosis Laboratory evaluation was significant for hemoglobin 5.9 g/dL, hematocrit 17.1%, MCV 80 fL, and an elevated RDW of 14.4%, consistent with normocytic anemia. Albumin was mildly reduced at 3.4 g/dL. CA 19–9, hepatic transaminases, coagulation studies, and renal function were all within normal limits (Table 1). The electrocardiogram demonstrated sinus tachycardia without ischemic changes. Chest radiography showed bilateral interstitial opacities compatible with pulmonary edema and cardiomegaly. TABLE 1Admission laboratory results. Flag denotes values outside the reference range (H = high, L = low). Reference ranges reflect the reporting laboratory.Laboratory testResultReference rangeFlag Complete Blood Count White blood cell count6.0 × 103/μL4.0–12.0 × 103/μLHemoglobin5.9 g/dL13.5–17.5 g/dLLHematocrit17.1%42.0%–49.5%LMCV80 fL80–100 fLRDW14.4%11.6%–14.0%HPlatelets324 × 103/μL150–400 × 103/μL Comprehensive Metabolic Panel BUN13 mg/dL6–23 mg/dLCreatinine1.05 mg/dL0.60–1.40 mg/dLAlbumin3.4 g/dL3.6–5.0 g/dLLTotal protein5.6 g/dL6.0–8.0 g/dLLIonized calcium1.15 mmol/L1.10–1.30 mmol/L Liver Function Tests AST10 U/L10–40 U/LALT12 U/L3–45 U/LAlkaline phosphatase50 U/L45–115 U/LTotal bilirubin0.4 mg/dL0.2–1.2 mg/dL Coagulation INR1.00.8–1.2 Inflammatory markers ESR52 mm/h0–15 mm/hHCRP< 1.0 mg/dL0.0–1.0 mg/dL Tumor markers CA 19–98 U/mL0–35 U/mL Other Lactate0.9 mmol/L0.2–1.8 mmol/L Admission laboratory results. Flag denotes values outside the reference range (H = high, L = low). Reference ranges reflect the reporting laboratory. Intravenous resuscitation, empirical intravenous proton pump inhibitor therapy, and packed red blood cell (pRBC) transfusions were initiated, with the patient requiring a total of five units of pRBCs during the hospitalization. Upper endoscopy identified a 5 cm actively bleeding mass in the second and third portions of the duodenum, distal to the ampulla of Vater (Figure 1). A three‐phase CT scan of the abdomen and pelvis demonstrated a radiopaque duodenal lesion of uncertain etiology, along with a 3.0 × 2.6 × 2.7 cm enhancing mass in the pancreatic head, for which a neoplastic process could not be excluded (Figure 2). Cross‐sectional imaging also identified a solitary pulmonary nodule measuring 9 mm, raising concern for additional metastatic disease. Medical Oncology was consulted, and further workup was initiated. Histopathological analysis of the duodenal biopsy demonstrated metastatic clear cell RCC, confirmed by an immunohistochemical profile positive for PAX8, CD10, and vimentin and negative for CK7 and CK20. In the context of the patient's nephrectomy performed 18 years prior with no evidence of metastatic disease at the time, the findings were consistent with delayed metastatic recurrence. Upper endoscopic view of the duodenum demonstrating a 5 cm mass involving the descending and proximal transverse duodenum (D2–D3), distal to the ampulla of Vater, with active bleeding (white arrow). Biopsy confirmed metastatic clear cell renal cell carcinoma. Contrast‐enhanced three‐phase computed tomography of the abdomen and pelvis (arterial phase) demonstrating a 3.0 × 2.6 × 2.7 cm enhancing mass in the pancreatic head (white arrow) with contiguous involvement of the adjacent duodenum (red arrow). Treatment Preoperative cross‐sectional imaging demonstrated a 9 mm solitary left lower lobe pulmonary nodule; however, no prior chest imaging was available for comparison. Given its small size and the absence of other features suggesting metastatic involvement, tissue sampling was deferred in favor of outpatient radiographic surveillance. The actively bleeding duodenal metastasis, which was the source of the patient's symptomatic anemia, required definitive management irrespective of the nodule's status. On multidisciplinary review, the disease was regarded as oligometastatic, and resection was undertaken to control hemorrhage and to characterize the pancreatic head lesion; decisions regarding systemic therapy were deferred to final surgical pathology and tumor board consensus. The patient was taken to the operating room on hospital Day 7 for a classic pancreaticoduodenectomy (Whipple procedure). Final surgical pathology confirmed metastatic clear cell RCC involving the pancreatic head and distal pancreas, with tumor extending through the outer wall of the muscularis propria into the duodenal mucosa with associated ischemic necrosis. The uncinate margin was positive for clear cell carcinoma, representing an R1 resection, while the bile duct margin was negative. All 15 retrieved lymph nodes were negative for metastatic carcinoma. The tumor was characterized as clear cell renal cell carcinoma; rhabdoid and sarcomatoid features were not specifically reported. An incidental segment 5 liver nodule proved to be a benign bile duct adenoma, and the gallbladder showed chronic acalculous cholecystitis with adenomyomatosis. Outcome and Follow‐Up The postoperative course was complicated by hypotension requiring vasopressor support, oliguria, symptomatic anemia requiring further transfusions, and an elevated drain amylase of 223 U/L on postoperative day (POD) 3 with a serum amylase of 18 U/L, raising concern for a postoperative pancreatic fistula (POPF). Although the patient showed initial clinical improvement with return of bowel function and normalization of renal function by POD 5, he subsequently developed sepsis with multiorgan failure requiring readmission to the ICU. CT imaging at that time revealed a large perihepatic fluid collection with air‐fluid levels, consistent with an intra‐abdominal abscess; findings suspicious for a hepaticojejunostomy (HJ) anastomotic leak; and a large right‐sided pleural effusion. Interventional radiology performed percutaneous drainage of the perihepatic collection with 1200 mL of output overnight, after which the patient improved markedly. Drain cultures grew Citrobacter species. By POD 10, the patient was confirmed to have a Grade B POPF and an HJ anastomotic leak, with bilious drain output of 1.6 L over 24 h. Percutaneous drainage had achieved adequate source control from a sepsis standpoint, and the leak was considered clinically controlled; however, definitive management was anticipated to require endoscopic stent placement across the hepaticojejunostomy to divert bile flow and promote anastomotic healing. As advanced endoscopy was not available at our institution, the patient was transferred to a tertiary center for ERCP with planned stenting of the hepaticojejunostomy. Discussion Renal cell carcinoma (RCC) accounts for 2% of all malignant neoplasms. It metastasizes in approximately 25% of cases, most commonly to the lungs, lymph nodes, liver, pancreas, bone, brain, skin, contralateral kidney, and adrenal glands [1]. Metastasis to the small intestine is rare, accounting for only 1%–2% of cases, typically presenting with upper gastrointestinal bleeding or obstructive symptoms and resulting in anemia, melena, fatigue, and early satiety [1, 3]. The clear cell subtype of RCC is the most common form to metastasize to the gastrointestinal tract [1]. Approximately 7% of small bowel metastatic lesions are of renal cell origin [3]. RCC metastases to the pancreas make up 2%–5% of all pancreatic neoplasms, with metastatic RCC being the most frequent secondary pancreatic tumor, followed by malignant melanoma and colorectal carcinoma [5, 7]. Approximately 20%–30% of RCC cases present synchronously with metastasis to distant organs. In addition, 20% of RCC patients initially diagnosed with nonmetastatic disease develop metastases during follow‐up, representing metachronous presentation [1]. The patient's family history of malignancies across three generations, including lung, prostate, testicular, and hematologic cancers, raises the question of a hereditary cancer predisposition. Although RCC is associated with several germline syndromes (VHL, BAP1, FH, and SDH‐deficient RCC), none of their defining features were present, and the familial pattern does not conform to these entities. The clustering of diverse tumors, including leukemia, might instead prompt consideration of a broader syndrome such as Li‐Fraumeni or Lynch, though it is not diagnostic of either. Germline testing was not performed, so the contribution of any hereditary predisposition to this delayed recurrence remains uncertain. The patient's relatively young age at the time of initial diagnosis (approximately 45 years) and family history would support consideration of germline evaluation and genetic counseling. RCC metastases often present years after initial treatment, with recurrences reported even up to 30 years after surgery [2]. It is therefore crucial to remain vigilant in post‐nephrectomy patients who present with new clinical symptoms. RCC can spread via lymphatic or hematogenous routes or through direct invasion into adjacent structures [8]. While the pancreas is a common site for RCC metastasis, the duodenum is a rare site, despite its retroperitoneal proximity to the right kidney [4, 8]. When it does occur, duodenal metastasis is most commonly located in the periampullary region or the duodenal bulb [4, 8]. In the present case, the duodenal involvement resulted from direct contiguous invasion rather than an independent metastatic deposit. Grossly, the tumor was centered in the pancreatic head and was described as passing through the duodenal wall from the pancreas, with histology confirming tumor extending through the muscularis propria into the duodenal mucosa, where it corresponded to the actively bleeding lesion identified endoscopically. Concomitant duodenal and pancreatic involvement of this type has been reported previously and reflects the intimate anatomic relationship of the two organs across the pancreaticoduodenal groove [6]. In this case, the duodenum and pancreatic head were densely adherent with tumor bridging the two, making the separation of their borders unfeasible. As a result, a classic pancreaticoduodenectomy was performed to resect the involved duodenum and pancreatic head en bloc, with final pathology showing a microscopically positive uncinate margin (R1 resection) with no lymph node involvement. Any patient with gastrointestinal symptoms and a history of RCC should undergo a comprehensive diagnostic workup, including both radiologic and endoscopic evaluations [2, 8]. Endoscopy is recommended to obtain biopsies of suspicious lesions, although it is not always necessary [8]. Angiography is particularly useful in diagnosing RCC metastases, as it typically reveals hypervascular tumors [9]. Surgical management should aim for complete metastasectomy when feasible [5, 10]. Reported procedures range from classic pancreaticoduodenectomy (Whipple procedure) to interventional embolization [8]. Transarterial embolization (TAE) represents an alternative for controlling hemorrhage in patients who are poor surgical candidates and is also used for unresectable primary or metastatic RCC [11]. Although enthusiasm has been tempered by concerns about ischemic complications given the shared vascular supply of the upper gastrointestinal tract, TAE has demonstrated favorable efficacy and safety in the broader literature on nonvariceal upper gastrointestinal bleeding [12, 13]. In the present case, however, the patient was an acceptable operative candidate with a bleeding, resectable lesion, and definitive surgical resection was therefore preferred over embolization. The positive uncinate margin (R1 resection) in this case has important implications for follow‐up. Dense adherence of tumor to the pancreatic head and retroperitoneal structures can make negative margins difficult to achieve, and microscopic residual disease confers a heightened risk of local recurrence; combined with the indeterminate pulmonary nodule and the deferral of systemic therapy, this warrants close postoperative surveillance with serial cross‐sectional imaging and continued multidisciplinary follow‐up. The need for subsequent systemic therapy is best determined by tumor board consensus, integrating the final pathology, margin status, and the behavior of the residual pulmonary nodule over time. The prognosis for patients with pancreatic metastasis is generally more favorable than for those with primary pancreatic carcinoma [5, 10]. Surgical resection of isolated pancreatic metastases, particularly from RCC, has been associated with improved survival, with 5‐year survival reaching up to 88%, even in cases of multifocal metastasis [5]. In contrast, metastases from other neoplasms often indicate widespread disease and carry a poorer prognosis, with 5‐year survival below 10% [5]. The European Association of Urology (EAU) supports metastasectomy as an appropriate treatment for most sites, except brain and possibly bone metastases, which are typically treated with stereotactic radiotherapy [14]. For localized RCC, nephrectomy remains the gold standard, while immunotherapy such as interferon alfa and interleukin‐2 is a primary treatment for advanced disease. However, immunotherapy is effective in only 10%–20% of patients [7]. For those with isolated metastases, seen in around 10% of metastatic RCC cases, complete resection can significantly improve long‐term survival [5]. Given the potential for favorable long‐term outcomes, we recommend that patients in the favorable‐risk group undergo surgical resection if technically feasible, even when other metastatic sites are present [5, 10]. Although a comparative trial between resection and nonresection would provide a definitive treatment guideline, the increasing safety of pancreatic resections at high‐volume centers and the potential for local symptoms from pancreatic neoplasms suggest that resection should be the preferred approach. Waiting for a multicenter international study may not be necessary in these cases [10]. The role of surgical resection in the presence of multiple pancreatic metastases from RCC remains controversial [5, 10]. Multifocal pancreatic metastases occur in 20%–45% of cases, with a reported rate of 39% in a review of 187 RCC‐related pancreatic metastasis cases [5]. That review showed that the outcomes of radical resection for multiple metastases were similar to those for solitary metastases, with no statistically significant differences in age, synchronicity, or time of onset [5]. This suggests that multifocality does not correlate with worse outcomes and should not be considered a contraindication to surgery. Regarding the type of surgical procedure, this remains another contentious issue in the treatment of pancreatic metastases from RCC. Most authors advocate for standard radical pancreatic resection over more conservative approaches to minimize the risk of recurrence [5, 10]. Consistent with the present case, late presentations of this kind continue to be reported, including concurrent pancreatic and periampullary RCC metastasis recurring 17 years after nephrectomy [15], reinforcing the need for indefinite clinical vigilance in patients with a remote history of RCC. Conclusion This case demonstrates that renal cell carcinoma can recur as gastrointestinal metastatic disease nearly two decades after curative nephrectomy, reinforcing the need for sustained clinical vigilance in patients with a remote history of RCC who present with anemia or gastrointestinal bleeding. Because metastatic duodenal and pancreatic lesions may mimic primary pancreaticobiliary tumors both radiographically and endoscopically, a systematic evaluation integrating cross‐sectional imaging, endoscopy, and immunohistochemical confirmation is essential to establish the diagnosis. For isolated metastatic disease, complete surgical resection, including pancreaticoduodenectomy when the duodenum and pancreatic head are jointly involved, offers the best opportunity for long‐term survival and remains the treatment of choice in appropriately selected patients. Nevertheless, the considerable perioperative morbidity of the Whipple procedure, including the postoperative pancreatic fistula and anastomotic leak observed in this patient, underscores the importance of careful patient selection and management at high‐volume centers. Author Contributions Adarsh Jha: writing – review and editing. Sai Sushrutha Mudupula Vemula: writing – review and editing. Rutwik Pradeep Sharma: investigation, writing – review and editing. Suhail Sapkota: resources, data curation, writing – review and editing. Sumugdha Rayamajhi: validation, supervision, project administration, writing – review and editing. Shreya Motkur: writing – review and editing. Ankit Kulkarni: conceptualization, data curation, investigation, writing – original draft. Funding The authors have nothing to report. Ethics Statement The authors have nothing to report. Consent Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the consent is available for review by the Editor‐in‐Chief on request. Conflicts of Interest The authors declare no conflicts of interest. Acknowledgments The authors have nothing to report. Data Availability Statement Data sharing is available on request from the authors. References Associated Data Data Availability Statement Data sharing is available on request from the authors.